LXEO Lexeo Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907108 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.3%
TTM EPS YoY54.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-62.4%
ROA-54.3%
ROIC (approx.)-88.6%
Asset turnover—
Leverage & solvency
Liabilities / assets11.2%
Debt / equity0.00x
Current ratio8.69x
Interest coverage-1,807.43x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | $654,000 |
| R&D expense | $63.80M | $74.09M | $53.13M | $49.16M |
| SG&A expense | $45.46M | $31.68M | $15.38M | $12.00M |
| Operating income | -$109.26M | -$105.77M | -$68.51M | -$60.51M |
| Interest expense | $95,000 | $137,000 | $205,000 | $91,000 |
| Pretax income | -$99.67M | -$98.44M | -$66.39M | -$59.28M |
| Income tax | $0 | $0 | — | — |
| Net income | -$99.96M | -$98.33M | -$66.39M | -$59.28M |
| EBITDA | -$108.99M | -$105.46M | -$68.24M | -$60.39M |
| EPS (basic) | -1.86 | -3.09 | -12.40 | -36.36 |
| EPS (diluted) | -1.86 | -3.09 | -12.40 | -36.36 |
| Weighted avg. shares (diluted) | 53.65M | 31.79M | 5.35M | 1.63M |
| Balance sheet | ||||
| Cash & equivalents | $63.00M | $38.27M | $124.72M | $80.59M |
| Short-term investments | $118.77M | $86.50M | — | — |
| Current assets | $188.39M | $126.12M | $124.29M | $80.05M |
| PP&E, net | $1.14M | $1.03M | $1.06M | $998,000 |
| Total assets | $268.69M | $146.94M | $139.81M | $97.08M |
| Current liabilities | $16.81M | $22.85M | $17.24M | $14.35M |
| Total liabilities | $22.02M | $30.10M | $26.27M | $25.00M |
| Shareholders' equity | $246.67M | $116.84M | $113.53M | -$112.95M |
| Shares outstanding | 73.00M | 33.07M | 26.65M | 1.61M |
| Cash flow statement | ||||
| Operating cash flow | -$98.56M | -$81.15M | -$59.50M | -$54.56M |
| Capital expenditure | $397,000 | $481,000 | $115,000 | $672,000 |
| Free cash flow | -$98.96M | -$81.63M | -$59.61M | -$55.23M |
| Investing cash flow | -$90.25M | -$94.08M | -$165,000 | -$901,000 |
| Financing cash flow | $216.79M | $88.78M | $103.79M | $189,000 |
| Depreciation & amortization | $268,000 | $304,000 | $271,000 | $120,000 |
| Stock-based compensation | $12.13M | $12.47M | $3.04M | $1.78M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.